Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Deanol→

Deanol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
108-01-0
Molecular formula
C4H11NO
Molecular weight
89.14 g/mol
Drug class
Dimethylaminoethanol (DMAE)choline-related nutritional compound
Mechanism of action
A small endogenous/nutritional molecule that can be metabolised in pathways related to choline and phospholipid synthesis. Proposed effects on acetylcholine availability are not sufficiently established as a clinical mechanism.
Indications / reported uses
  • No broadly established or universally authorised therapeutic indication as a medicinal API; dietary-supplement uses and health claims are jurisdiction-specific and should not be presented as approved treatment for cognitive or psychiatric disorders

Sources: PubChem — Dimethylaminoethanol · NLM MeSH — Deanol · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Deanol Environmental Risk Assessment (ERA) (the Deanol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.